The Bull Rankings scorecard — our quality-growth score is 71.1 / 100, built from three pillars scored 0–100: Quality 76, Growth 87, Value 54 (valuation is judged against sector peers).
The thesis
Indivior’s current price of $35.99 sits on the cheap side of its sector, with a P/S of 3.2x that the Bull Rankings model flags as below the Healthcare median (≈40th percentile). That alone suggests the market is under‑pricing the company’s revenue engine. The model’s quality‑growth score of 71.1/100 is driven by a Growth pillar of 87 and a Quality pillar of 76. The Value pillar, at 54, confirms the stock is priced on the cheaper end of its peer group. The strongest signal—Buying back stock—shows management believes the shares are undervalued and is actively returning capital to shareholders. Together, these data points argue that INDV is a value play with a high‑growth engine that deserves a closer look.
What the business actually is
Indivior develops, manufactures, and sells buprenorphine‑based prescription drugs for opioid dependence. Its flagship products are SUBLOCADE (a monthly extended‑release injection) and SUBOXONE (a buprenorphine‑naloxone sublingual film). The company also markets SUBOXONE Tablet and SUBUTEX Tablet, both buprenorphine sublingual formulations for opioid use disorder. These products serve clinicians and patients in the United States, Europe, Canada, Australia, and other international markets, positioning Indivior as a niche player in the specialty drug space.
Why it can (or can't) keep compounding
Margins remain razor‑sharp: a profit margin of 26.7% in the latest quarter underscores efficient cost control and pricing power. Revenue grew 13.5% YoY, a solid pace for a specialty drug company that is still expanding its patient base. The company’s free cash flow of –$111m signals heavy reinvestment, but the negative figure is offset by the Buying back stock signal, implying a future shift toward positive cash generation once the company scales. Indivior’s moat lies in its narrow, FDA‑approved product portfolio and the entrenched relationships with addiction treatment centers. Competitors would need to replicate the complex regulatory approvals and build comparable distribution networks, a barrier that is not easily surmounted.
The valuation question
The P/S of 3.2x places INDV below the Healthcare median, indicating the market values its sales at a modest premium. The reverse DCF offers no read because free cash flow is negative, so we rely on the multiple and the model’s Value pillar. With a Value score of 54, the stock is priced on the cheaper side of its peers, suggesting the market has not fully absorbed the company’s growth trajectory. The model’s Growth pillar of 87 reflects a revenue growth of 13.5%, far above the sector average, yet the price does not yet reflect the implied future earnings that such growth could generate. In short, optimism about growth is not yet priced in, and the current price leaves room for upside if the company continues to expand its patient base.
The bear case
The most compelling risk is the negative free cash flow of –$111m. A cash‑negative position limits the company’s ability to fund R&D, pursue acquisitions, or weather downturns in the opioid treatment market. If the company cannot reverse this trend, the Buying back stock signal may evaporate, and the stock could retreat toward its 52‑week low of $22.56. A sustained decline in revenue growth below the current 13.5% would also erode the high Growth pillar, undermining the valuation case.
What would change our mind
- Free cash flow turns positive: A shift from –$111m to a positive figure would validate the company’s ability to fund growth and support the stock‑buyback signal.
- Revenue growth dips below 10%: A slowdown would weaken the Growth pillar from 87 to a lower score, pulling the overall quality‑growth score down.
- P/S climbs above 5x: If the market starts pricing sales at a higher multiple, the Value pillar would rise above 54, indicating the stock is no longer cheap and reducing the upside potential.
These thresholds are anchored to the latest quarter ended 2026‑06‑30, ensuring that any shift in the data would materially alter the investment thesis.